Search Result

Results for "

P2X4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Antibiotic (1) Autophagy (2) Bacterial (1) Calcium Channel (1) Caspase (2) CXCR (1) Dengue Virus (1) Endogenous Metabolite (1) Environmental Pollutants (2) Flavivirus (1) HIV (2) HSV (1) Interleukin Related (2) Isotope-Labeled Compounds (2) Mitophagy (1) NOD-like Receptor (NLR) (2) NTPDase (1) Nucleoside Antimetabolite/Analog (1) P2X Receptor (29) P2Y Receptor (2) Parasite (1) Prostaglandin Receptor (2) Reference Standards (2) SARS-CoV (1) Small Interfering RNA (siRNA) (2) α-synuclein (2)
By Research Areas:	Cancer (6) Cardiovascular Disease (5) Endocrinology (1) Infection (2) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (19)
Oligonucleotides:	Nucleotide Analogs (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) Cytidine Nucleotide (1) siRNAs (2)

Inhibitors & Agonists

Fluorescent Dye

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15310

Ivermectin 45+ Cited Publications MK-933; CD-5024; K-237	Environmental Pollutants Antibiotic Mitophagy Bacterial Parasite Autophagy Flavivirus HSV HIV SARS-CoV Dengue Virus	Infection Cancer
Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of *P2X₄* and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .

HY-136254

BzATP triethylammonium salt 10+ Cited Publications	P2X Receptor	Inflammation/Immunology Cancer
BzATP triethylammonium salt acts as a P2X receptor agonist with pEC₅₀s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively . BzATP triethylammonium salt is potent at P2X7 receptors with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively .

HY-D0914

Fast Green FCF FD&C Green No. 3; Food green 3; C.I. 42053	Environmental Pollutants α-synuclein	Neurological Disease
Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and *P2X4* receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

HY-130605

BAY-1797 4 Publications Verification	P2X Receptor	Neurological Disease
BAY-1797, a chemical probe, is a potent, orally active, and selective *P2X4* antagonist, with an IC₅₀ of 211 nM against human P2X4. BAY-1797 displays no or very weak activity on the other P2X ion channels. BAY-1797 shows anti-nociceptive and anti-inflammatory effects .

HY-101911

5-BDBD 4 Publications Verification	P2X Receptor	Neurological Disease
5-BDBD, a potent and selective *P2X4* receptor antagonist, inhibits rP2X4R-mediated currents, with an IC₅₀ of 0.75 μM. 5-BDBD completely blocks the basal and acute hyperalgesia induced by nitroglycerin (NTG) .

HY-101910

PSB-12062 1 Publications Verification N-(p-Methylphenylsulfonyl)phenoxazine	P2X Receptor	Neurological Disease
PSB-12062 is a potent and selective *P2X4* antagonist with an IC₅₀ of 1.38 μM for human P2X4.

HY-110237

BX430	P2X Receptor Calcium Channel	Cardiovascular Disease
BX430 is a potent and selective noncompetitive allosteric *human P2X4* receptor channels antagonist with an IC₅₀** of 0.54 μM. BX430 has species specificity. BX430 is used for chronic pain and cardiovascular disease.

HY-160645

P2X4 antagonist-1	P2X Receptor	Neurological Disease Endocrinology Cancer
P2X4 antagonist-1 is a P2X4 receptor antagonist with an IC₅₀ of 15 nM. P2X4 antagonist-1 inhibits ATP (HY-B2176)-induced calcium influx. P2X4 antagonist-1 can be used for the research of pain syndromes, endometriosis, cancer .

HY-150270A

NP-1815-PX sodium	P2X Receptor Prostaglandin Receptor NOD-like Receptor (NLR) Caspase Interleukin Related	Inflammation/Immunology
NP-1815-PX sodium is an orally active dual inhibitor of *P2X4* and prostaglandin TP receptors, with an IC₅₀ of 0.26 μM against human *P2X4* receptors. NP-1815-PX sodium specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX sodium selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX sodium not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX sodium exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX sodium is used in studies related to asthma and inflammatory bowel disease (colitis) .

HY-D0976

NF279 1 Publications Verification	P2X Receptor HIV NTPDase CXCR	Infection
NF279 is a selective P2X1 receptor antagonist and NTPDase inhibitor, with a P2X1 IC₅₀ value of 19 nM. NF279 suppresses GABA-evoked currents, reduces ATP-excited respiratory activity, alters hypoglossal nerve burst parameters, and blocks CXCR4, CCR5, CXCR3, and CXCR7-mediated calcium responses. NF279 arrests HIV-1 fusion downstream of CD4 binding, inhibits R5- and X4-tropic HIV-1 strains. NF279 can be used for the research of HIV-1 infection .

HY-131502

Taspine	P2X Receptor	Inflammation/Immunology
Taspine is a natural product with anti-inflammatory activity. Taspine suppresses *P2X4* receptor activity via PI3K inhibition. Taspine inhibits pro-inflammatory signalling via inhibition of P2X4 receptors in macrophage .

HY-134807

Indophagolin	P2X Receptor 5-HT Receptor Autophagy	Cancer
Indophagolin is a potent, indoline-containing autophagy inhibitor (IC₅₀=140 nM). Indophagolin antagonizes the purinergic receptor *P2X₄* as well as P2X₁ and P2X₃ with IC₅₀s of 2.71, 2.40 and 3.49 μM, respectively. Indophagolin also antagonizes the G_q-protein-coupled P2Y₄, P2Y₆, and P2Y₁₁ receptors (IC₅₀s =3.4~15.4 μM). Indophagolin has a strong antagonistic effect on serotonin receptor 5-HT₆ (IC₅₀=1.0 μM) and a moderate effect on receptors 5-HT_1B, 5-HT_2B, 5-HT_4e, and 5-HT₇ .

HY-108676

NF023 hexasodium 1 Publications Verification	P2X Receptor	Neurological Disease
NF023 hexasodium is a selective and competitive P2X₁ receptor antagonist, with IC₅₀ values of 0.21 μM, 28.9 μM, > 50 μM and > 100 μM for human P2X₁, P2X₃, P2X₂, and P2X₄-mediated responses respectively .

HY-W013707

Cytidine-5'-triphosphate disodium dihydrate 3 Publications Verification Cytidine triphosphate disodium dihydrate; 5'-CTP disodium dihydrate	Endogenous Metabolite	Metabolic Disease
Cytidine-5'-triphosphate disodium dihydrate (5'-CTP disodium dihydrate) is a molecule of high energy, and acts as a coenzyme in glycerophospholipid biosynthesis and protein glycosylation .

HY-101308A

MRS2179 tetrasodium hydrate 2 Publications Verification	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium hydrate is a competitive P2Y1 receptor antagonist, with a K_b of 102 nM and a pA₂ of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium hydrate inhibits platelet aggregation .

HY-W097612

P2X4 antagonist-5	P2X Receptor	Others
P2X4 antagonist-5 (compound 63) is a control compound for *P2X4* antagonists (IC₅₀>100 μM, hP2X4) .

HY-170804

P2X4 antagonist-3	P2X Receptor	Neurological Disease Inflammation/Immunology Cancer
P2X4 antagonist-3 (Compound 14c) is a *P2X4* antagonist with an IC₅₀ value of 1.2 μM. P2X4 antagonist-3 is promising for research of neuroinflammation, chronic pain, and cancer progression .

HY-18745

BzATP triethylammonium Benzoylbenzoyl-ATP triethylammonium	P2X Receptor	Inflammation/Immunology Cancer
BzATP triethylammonium acts as a P2X receptor agonist with pEC₅₀s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively . BzATP triethylammonium is potent at P2X7 receptors with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively .

HY-160677

P2X4 antagonist-2	P2X Receptor	Neurological Disease
P2X4 antagonist-2 is an antagonist for *P2X4* with an IC₅₀ of 24 nM .

HY-168474

P2X4 antagonist-4	P2X Receptor	Inflammation/Immunology
P2X4 antagonist-4 (compound 64) is a potent *P2X4R* antagonist with an IC₅₀ value of 8 µM. P2X4 antagonist-4 blocks the ATP-induced NLRP3 inflammasome activation and release of IL-1β .

HY-101228

PSB-12054	P2X Receptor	Neurological Disease
PSB-12054 is a selective *P2X4* antagonist with an IC₅₀ of 0.189 μM at human P2X4 receptors. PSB-12054 can be used in the research of neuropathic pain and neurodegenerative diseases .

HY-176195

P2X4-IN-1	P2X Receptor	Neurological Disease
P2X4-IN-1 (Compound 1) is an orally active *P2X4* inhibitor. P2X4-IN-1 can be used in the study of prophylaxis disease .

HY-150270

NP-1815-PX	Prostaglandin Receptor P2X Receptor NOD-like Receptor (NLR) Caspase Interleukin Related	Neurological Disease Inflammation/Immunology
NP-1815-PX is an orally active dual inhibitor of *P2X4* and prostaglandin TP receptors, with an IC₅₀ of 0.26 μM against human *P2X4* receptors. NP-1815-PX specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX is used in studies related to asthma and inflammatory bowel disease (colitis) .

HY-176731

MSK-9	P2X Receptor	Neurological Disease
MSK-9 is a positive allosteric modulator of the *P2X4* receptor with dual activities of enhancing ion conductance and delaying receptor inactivation. MSK-9 stabilizes the open state of the P2X4 receptor through rigid 3-piperidinyl and hydrophobic menthyl substituents. MSK-9 can be used in the study of multiple sclerosis (MS) .

HY-101308

MRS2179 tetrasodium	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium is a competitive P2Y1 receptor antagonist, with a K_b of 102 nM and a pA₂ of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium inhibits platelet aggregation .

HY-151547

MRS4719	P2X Receptor	Neurological Disease
MRS4719 is a potent P2X4 receptor antagonist with an IC₅₀ value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca ²⁺]_i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke .

HY-151546

MRS4596	P2X Receptor	Neurological Disease
MRS4596 is a potent and selective P2X4 receptor antagonist with an IC₅₀ value of 1.38 μM for human P2X4 receptor. MRS4596 has neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4596 can be used in research of ischemic stroke .

HY-151546S

MRS4596-d4	Isotope-Labeled Compounds P2X Receptor	Neurological Disease
MRS4596-d₄ is the deuterium labeled MRS4596 (HY-151546). MRS4596 is a potent and selective P2X4 receptor antagonist with an IC₅₀ value of 1.38 μM for human P2X4 receptor. MRS4596 has neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4596 can be used in research of ischemic stroke .

HY-151547S

MRS4719-d3	Isotope-Labeled Compounds P2X Receptor	Neurological Disease
MRS4719-d₃ is the deuterium labeled MRS4719 (HY-151547). MRS4719 is a potent P2X4 receptor antagonist with an IC₅₀ value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca ²⁺]_i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke .

HY-D0914A

Fast green FCF free acid	α-synuclein	Neurological Disease
Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as Aβ, *P2X4* receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

HY-101910R

PSB-12062 (Standard) N-(p-Methylphenylsulfonyl)phenoxazine (Standard)	Reference Standards P2X Receptor	Neurological Disease
PSB-12062 (Standard) is the analytical standard of PSB-12062 (HY-101910). This product is intended for research and analytical applications. PSB-12062 is a potent and selective P2X4 antagonist with an IC₅₀ of 1.38 μM for human P2X4.

HY-RS09906

P2RX4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
P2RX4 Human Pre-designed siRNA Set A contains three designed siRNAs for P2RX4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

P2RX4 Human Pre-designed siRNA Set A P2RX4 Human Pre-designed siRNA Set A

HY-101911R

5-BDBD (Standard)	Reference Standards P2X Receptor	Neurological Disease
5-BDBD (Standard) is the analytical standard of 5-BDBD (HY-101911). This product is intended for research and analytical applications. 5-BDBD, a potent and selective P2X4 receptor antagonist, inhibits rP2X4R-mediated currents, with an IC₅₀ of 0.75 μM. 5-BDBD completely blocks the basal and acute hyperalgesia induced by nitroglycerin (NTG) .

HY-137606

Uridine adenosine tetraphosphate UP4A	P2X Receptor	Cardiovascular Disease
Uridine adenosine tetraphosphate (UP4A) is an endothelium-derived vasoconstrictor that primarily acts through the P2X1 receptor and possibly through the P2Y2 and P2Y4 receptors. Uridine adenosine tetraphosphate can be used in the study of cardiovascular diseases .

HY-186112

PSFL2915	P2X Receptor	Inflammation/Immunology
PSFL2915 is a P2X receptor inhibitor with oral effectiveness, with an IC₅₀ of 0.319 μM for human P2X3, 0.261 μM for rat P2X2/3, and 13.3 μM for human P2X2, and exhibits ~42-fold selectivity for human P2X3 over human P2X2. PSFL2915 inhibits human P2X3 activation by preventing allosteric tightening of the inner pocket of the head domain required for channel opening, with magnesium-dependent inhibition. PSFL2915 inhibits rat P2X2/3 and human P2X2 receptor activation, and has low activity against human P2X1, *P2X4, and P2X7* receptors. PSFL2915 can be used for the research of chronic cough .

HY-RS09907

P2rx4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
P2rx4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for P2rx4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

P2rx4 Mouse Pre-designed siRNA Set A P2rx4 Mouse Pre-designed siRNA Set A

HY-182642

MRS2339	P2X Receptor Nucleoside Antimetabolite/Analog	Cardiovascular Disease
MRS2339 is a ribose-modified nucleotide and a nucleotidase-resistant P2 receptor agonist. MRS2339 activates P2X4R. MRS2339 induces ionic currents via P2X receptors, reduces cardiomyocyte cross-sectional area and heart weight/body weight ratio, lacks vasodilatory activity, and extends the lifespan of mice with cardiomyopathy. MRS2339 can be used in research related to heart failure and cardiomyopathy .

Cat. No.	Product Name	Type

HY-D0914

Fast Green FCF FD&C Green No. 3; Food green 3; C.I. 42053	Fluorescent Dye
Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and *P2X4* receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

Fast Green FCF

FD&C Green No. 3; Food green 3; C.I. 42053

Fluorescent Dye

Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and P2X4 receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

HY-D0914A

Fast green FCF free acid	Fluorescent Dye
Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as Aβ, *P2X4* receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

Fast green FCF free acid

Fluorescent Dye

Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as Aβ, P2X4 receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15310

Ivermectin 45+ Cited Publications MK-933; CD-5024; K-237	Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Antiviral Anti-parasitic Disease Research Disease Research Fields Source Classification Cancer	Environmental Pollutants Antibiotic Mitophagy Bacterial Parasite Autophagy Flavivirus HSV HIV SARS-CoV Dengue Virus
Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of *P2X₄* and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .

Cat. No.	Product Name	Chemical Structure

HY-151546S

MRS4596-d4
MRS4596-d₄ is the deuterium labeled MRS4596 (HY-151546). MRS4596 is a potent and selective P2X4 receptor antagonist with an IC₅₀ value of 1.38 μM for human P2X4 receptor. MRS4596 has neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4596 can be used in research of ischemic stroke .

HY-151547S

MRS4719-d3
MRS4719-d₃ is the deuterium labeled MRS4719 (HY-151547). MRS4719 is a potent P2X4 receptor antagonist with an IC₅₀ value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca ²⁺]_i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke .

MRS4719-d3

MRS4719-d₃ is the deuterium labeled MRS4719 (HY-151547). MRS4719 is a potent P2X4 receptor antagonist with an IC₅₀ value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca ²⁺]_i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

P2X4

Inhibitors & Agonists

Fluorescent Dye

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products